ZonMw currently has an open grant round for research into existing medications that may also be promising for patients with ME/CFS. This is a chronic illness that affects multiple systems in the body at the same time.
De Volkskrant published an article on this topic on March 13. Below is an explanation from ZonMw.
In short: this round is aimed at encouraging research into affordable and available medication for ME/CFS patients in the Netherlands. With this round, ZonMw is promoting research into existing non‑patented medicines, because these offer the greatest chance of rapid availability for patients and affordability.
For ME/CFS patients, it is extremely important that medication becomes available in the short term for this severe illness. At the moment, there is no effective treatment available for ME/CFS patients.
From a scientific perspective, it is relevant to include all medications that may be effective in this research. At the same time, it is also important that medications are promising in terms of rapid availability for patients and affordability. That chance is greatest with non‑patented medicines. That is why this grant round focuses on stimulating research into drugs that are scientifically promising
and likely to be quickly accessible.
In addition, ZonMw works with public funds. This means that the results of research must benefit society as a whole. They also must not lead to exclusive market advantages for a single party. It is also important that knowledge and results, especially for a relatively unknown illness like ME/CFS, are made widely available.
It is not the case that patented medicines are by definition excluded from a ZonMw program. For each grant round, a choice is made based on the goal of that round, with the above arguments carefully weighed. This means that the grant conditions may differ between rounds.
Within the research program, the involvement of people with lived experience plays an important role. They participate as committee members, advisory group members, or reviewers in the program. People with lived experience are also involved in the research projects and in shaping this grant round.
The ME/CFS research program runs until 2031, with a total budget of 32.9 million euros. Several more grant rounds for biomedical and clinical research will follow.
For more information about the program, see:
https://lnkd.in/emtmb3Xv